Pure Global AI
NCT06309511Recruiting

Subendocardial Viability Ratio in Hypertension

Istituto Auxologico ItalianoClinicalTrials.govdiagnostic test
Verified
Study focus
Disease/Condition
Hypertension
Drug/Device/Intervention
Arterial tonometry
Study type
Observational
Intervention type
diagnostic test
Sponsor & location
Primary sponsor
Istituto Auxologico Italiano
Location
Mascalucia,Bari,Milano,Reggio Emilia,Trieste, Italy
Timeline & enrollment
Phase
N/A
Start date
Oct 01, 2022
End date
Dec 31, 2026
Enrollment
3000 participants
Primary outcome

Buckberg index

Summary

The aim of the research is to evaluate the Subendocardial Viability Ratio (SEVR) in
 hypertensive patients, using non-invasive arterial tonometry, and to establish the
 influencing factors and the possibility of predicting cardiovascular morbidity and mortality
 in arterial hypertension.
 
 The SEVR will be evaluated on all patients belonging to the Arterial Hypertension Centers
 undergoing non-invasive arterial tonometry.
 
 The SEVR is calculated on the morphology of the central pressure wave as the ratio between
 the DPTI (diastolic pressure-time index), i.e. the area between the carotid pressure curve
 and the ventricular pressure curve during the diastolic phase, and the SPTI ( systolic
 pressure-time index), i.e. the area under the carotid pressure curve during the systolic
 phase.
 
 The SEVR will be correlated with the anthropometric and pathology variables which will be
 collected in an appropriate database.

ICD-10 classifications
Hypertensive diseasesRenovascular hypertensionSecondary hypertensionOther secondary hypertensionHypertensive heart disease
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06309511
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06309511 through Pure Global AI's free database. This phase not specified trial is sponsored by Istituto Auxologico Italiano and is currently Recruiting. The study focuses on Hypertension. Target enrollment is 3000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.